Preoperative Chemoradiotherapy Extends Survival in Pancreatic Cancer

Audio Journal of Oncology Podcast

CHICAGO—Patients with resectable and “borderline resectable” pancreatic cancers treated with chemoradiation before surgery (followed by adjuvant chemotherapy) had significantly improved outcomes compared to those randomized to have surgery first and adjuvant chemotherapy in the Dutch Pancreatic Cancer Group’sPREOPANC-1 randomized, controlled, multicenter phase III trialreported at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO).

https://meetinglibrary.asco.org/record/160063/abstract

Although fewer tumors could be resected in patients treated with preoperative therapy compared with those on standard care (down from 72 to 62 per cent) there was a markedly increased rate of complete resections, said study author Geertjan Van Tienhoven MD, PhD, a radiation oncologist at the Academic Medical Center in Amsterdam, Netherlands, who is a member of the Dutch Pancreatic Cancer Group. He discusses the PREOPANC-1 study implications with the Audio Journal of Oncology.